PerMed FH - Personalising diagnosis and treatment for Familial Hypercholeserolaemia patients

Studies, Data & Research

Driving scientific progress and delivering innovation for FH patients and families.

Unveiling the Role of APOB Variants in Familial Hypercholesterolemia: Functional Insights

Author(s): Maria Ferreira
Congress: 93rd European Atherosclerosis Society (EAS) congress
Date/Location: Glasgow, UK on 4-7 May 2025
Download

Regulatory Variants in LDLR and PCSK9 promoters and 5´UTRs: investigating the impact in Familial Hypercholesterolemia

Author(s): Rafael Graça
Congress: 93rd European Atherosclerosis Society (EAS) congress
Date/Location: Glasgow, UK on 4-7 May 2025
Download
The project leading to these results has received funding from “la Caixa” Foundation and FCT, I.P. under the project code: LCF/PR/HP23/52330032. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the "la Caixa" Foundation or the FCT. Neither "la Caixa" Foundation nor the FCT can be held responsible for them.
© 2026 - PerMed FH

PerMedFH
Symposium

3–4 December 2026
Sintra, Portugal

International Symposium on Personalised Medicine in Familial Hypercholesterolaemia (FH)

Join us online and be part of the discussion on the future of personalised diagnosis and treatment in Familial Hypercholesterolaemia.

Online participation is free of charge, but registration is required.

Explore the symposium